Molecular Partners (NASDAQ:MOLN) Trading Up 2.2% - Time to Buy?

Molecular Partners AG (NASDAQ:MOLN - Get Free Report)'s stock price traded up 2.2% on Monday . The company traded as high as $3.89 and last traded at $3.89. 657 shares were traded during mid-day trading, a decline of 97% from the average session volume of 20,207 shares. The stock had previously closed at $3.80.

Analyst Upgrades and Downgrades

Separately, Lifesci Capital assumed coverage on shares of Molecular Partners in a research note on Tuesday, March 11th. They set an "outperform" rating and a $12.00 price objective on the stock.

Molecular Partners Stock Down 2.2%

The firm has a market cap of $153.22 million, a price-to-earnings ratio of -1.77 and a beta of 1.11. The firm has a fifty day moving average price of $3.89 and a 200-day moving average price of $4.63.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.11). Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. Equities research analysts anticipate that Molecular Partners AG will post -1.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. Suvretta Capital Management LLC raised its stake in Molecular Partners AG (NASDAQ:MOLN - Free Report) by 455.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,221,494 shares of the company's stock after purchasing an additional 1,821,494 shares during the quarter. Suvretta Capital Management LLC owned about 5.50% of Molecular Partners worth $10,548,000 at the end of the most recent quarter. 26.55% of the stock is owned by institutional investors and hedge funds.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.